PRTODAY / NewswireToday Free press release distribution service network

Written by / Agency / Source: tebu-bio

Check Ads Availability|e-mail Article


Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!

tebu-bio Celebrates 10 Years Serving the ADME Community - tebu-bio, today announced its first ADME seminar in Paris to celebrate 10 years serving the ADME-Tox community (October 9th; Maison de la Chimie, France) - tebu-bio.com
tebu-bio Celebrates 10 Years Serving the ADME Community

 

NewswireToday - /newswire/ - Le Perray en Yvelines, Yvelines, France, 2008/07/02 - tebu-bio, today announced its first ADME seminar in Paris to celebrate 10 years serving the ADME-Tox community (October 9th; Maison de la Chimie, France) - tebu-bio.com.

   
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma/BioTech/Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

This first ADME seminar, “From in vitro ADME studies to pharmacokinetics prediction”, aims to provide European experts with an overview of the latest technologies in the ADME-Tox and early-ADME fields. Scientists will get an accurate picture of ADME-Tox properties, drug-drug interactions, transporters assessment and pharmacokinetics prediction. The participants will have the opportunity to discuss their upcoming projects and research programs with tebu-bio product specialists and leading world-wide manufacturers (Advancell, Cypex, Noray Bio, Solvo Biotechnology, Xenotech, tebu-bio laboratories).

“We wanted to develop the European ADME-Tox network by creating a forum where experts in the ADME-Tox enviroment can discuss the latest advances in their field.” said Donald van Dijk, CEO of tebu-bio.

“It’s a fantastic opportunity to thank our ADME customers who have worked with us for the last 10 years, since tebu-bio became the first company to introduce cryopreserved hepatocytes in Europe” added Dr Lecommandeur, VP Business Development Manager.

This seminar will take place in the historic French conference centre “La Maison de la Chimie” in Paris (room 201; October 9th, 2008).

Seminar programme, registration form, and accommodation details are available online.

About tebu-bio

tebu-bio (tebu-bio.com) is an expert in the supply and distribution of reagents for Life Sciences research in Europe and has its own R&D laboratories which provide contract services.
tebu-bio is selected as a provider by the most demanding customers and is chosen as a distribution partner by renowned specialized providers. With more than 425,000 specialized reagents, tebu-bio’s on-line catalogue tebu-bio.com is updated daily in the fields of ADME-tox studies but also recombinant protein production, pharmaceutical target validation, molecular screening and cell-based assays. This broad range of reagents and services puts tebu-bio in a strong position to supply the largest international pharmaceutical companies, biotech organizations and Research Institutes in Europe.

tebu-bio: the smarter way to buy research products in Europe

 
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma/BioTech/Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

Written by / Agency / Source: tebu-bio

 
 

Availability: All Regions (Including Int'l)

 

Traffic Booster: [/] Quick Newswire Today Visibility Checker

 

Distribution / Indexing: [+] / [Company listed above is a registered member of our network. Content made possible by PRZOOM / PRTODAY indexing services]

 
 
# # #
 

 
  Your Banner Ad showing on ALL
Pharma/BioTech/Nutrition articles,
CATCH Visitors via Your Competitors Announcements!


tebu-bio Celebrates 10 Years Serving the ADME Community

Company website links NOT available to basic submissions
It is OK to republish and/or LINK any newswire for any legitimate media purpose as long as you name Newswire Today and LINK as the source.
 
  Is this your article?
Activate ALL web links and social stream by Upgrading to Press Release PREMIUM Plan Now!

|
Publisher Contact: Philippe Fixe - tebu-bio.com 
+33(0)1 30 46 39 00 philippe.fixe[.]tebu-bio.com
 
Newswire Today - PRZOOM / PRTODAY disclaims any content contained in this article. If you need/wish to contact the company who published the current release, you will need to contact them - NOT us. Issuers of articles are solely responsible for the accuracy of their content. Our complete disclaimer appears here.
IMPORTANT INFORMATION: Issuance, publication or distribution of this press release in certain jurisdictions could be subject to restrictions. The recipient of this press release is responsible for using this press release and the information herein in accordance with the applicable rules and regulations in the particular jurisdiction. This press release does not constitute an offer or an offering to acquire or subscribe for any tebu-bio securities in any jurisdiction including any other companies listed or named in this release.

Pharma/BioTech/Nutrition via RSSAdd NewswireToday - PRZOOM Headline News to FeedBurner
Find who RetweetFollow @NewswireTODAY



Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!


Read Latest Articles From tebu-bio / Company Profile


Read Pharma/BioTech/Nutrition Most Recent Related Newswires:

U.S. FDA Approves New Indication for Ipsen’s Somatuline® Depot (lanreotide) Injection for the Treatment of Carcinoid Syndrome
Genentech Provides Update on First Lampalizumab Phase III Study for Geographic Atrophy, an Advanced Form of Age-Related Macular Degeneration
mProve Health and Greenphire Partner to Deliver a First-of-its-Kind Patient Engagement Solution
FDA Approves Genentech’s Actemra (Tocilizumab) for the Treatment of CAR T Cell-Induced Cytokine Release Syndrome
Greenphire Named to Inc. 5000 for Fifth Consecutive Year
Five Community Health Centers Honored for Innovative Approaches to Medication Therapy Management
FDA Grants Priority Review for Genentech’s Gazyva in Previously Untreated Follicular Lymphoma
ProSci Incorporates Flow Cytometry Screening to Custom Monoclonal Antibody Service
FDA Grants Priority Review to Genentech's Emicizumab for Hemophilia A with Inhibitors
BD Expands Suite of Blood Culture Offerings with New BD BACTEC™ Standard Aerobic & Standard Anaerobic Plastic Bottles
Twist Bioscience Collaborates with Synbio Technologies to Supply Long DNA to Customers
FDA Grants Priority Review and Breakthrough Therapy Designation for Zelboraf (vemurafenib) in Erdheim-Chester Disease with BRAF V600 Mutation
Ipsen Receives Positive CHMP Opinion for Approval of Xermelo® (telotristat Ethyl)
BD Receives FDA 510(k) Clearance for New Immunological Diagnostic System
Positive Phase III Results for Genentech’s Emicizumab in Hemophilia A Published in The New England Journal of Medicine

Boost Your Social Network
& Crowdfunding Campaigns


LIFETIME SOCIAL MEDIA WALL
NewswireToday Celebrates 10 Years in Business


PREMIUM Members


Visit  BizJobs.com

Visit  RightITnow Ltd





 
  ©2017 Newswire Today — Limelon Advertising, Co.
Home | About | Advertise/Pricing | Contact | Investors | Privacy/TOS | Sitemap | FRANCAIS
newswire, PR press releases distribution service magazines engine news alert newsroom press room breaking news public relations articles company news alerts newswiredistribution ezine bizentrepreneur biznewstoday digital business report market search pr firms agencies reports distri-bution today investor relation successful internet entrepreneurs newswire distribution prtoday.com freenewswiredistribution asianewstoday bizwiretoday USA pr UK today - NOT affiliated with PRNewswire as we declined their partnership offer in 2013
 
PRTODAY & NewswireTODAY are NOT affiliated with USA TODAY (usatoday.com)